this is a navigational image map, please load this image to continue.

 

On-demand IC351 (Cialistrade mark) enhances erectile function in patients with erectile dysfunction.

Source: Int J Impot Res 2001 Feb; 13(1): 2-9

Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC.

Keck School of Medicine, University of Southern California, Los Angeles, California, USA.


IC351 (Cialistrade mark) is a selective inhibitor of PDE5. The efficacy and safety of on-demand dosing of IC351 in men with erectile dysfunction was assessed in a multicenter, double-blind, placebo-controlled study. One hundred seventy-nine men (mean age: 56 y) were randomized to receive placebo or IC351 at doses of 2, 5, 10 or 25 mg, taken on demand over a 3-week period. The primary endpoints were change from baseline in responses to Questions 3 (Q3) and 4 (Q4) of the International Index of Erectile Function (IIEF). IC351 significantly improved IIEF Q3 scores at all doses vs placebo (P

The most common adverse events were headache and dyspepsia. The conclusion of this study was that on-demand IC351 at doses up to 25 mg was well tolerated and significantly improved erectile function.

 

this is a navigational image map, please load this image to continue.